Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 source : Www.achievelifesciences.com save search
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Published: 2022-01-25 (Crawled : 13:30) - achievelifesciences.com
ACHV | $4.41 -2.22% -2.27% 82K
|
Health Technology
|
| O: -0.99%
H: 4.56%
C: 1.78%
trial life science phase 3
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Published: 2022-01-04 (Crawled : 14:00) - achievelifesciences.com
ACHV | $4.41 -2.22% -2.27% 82K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
trial life science phase 3
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Published: 2021-11-22 (Crawled : 13:30) - achievelifesciences.com
ACHV | $4.41 -2.22% -2.27% 82K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
life science phase 3 trial
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.